

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dave S.B. HOON and Hiroya TAKEUCHI

Serial No: Not Yet Assigned

Filed: Herewith

For: DETECTION OF MICROMETASTASIS OF
MELANOMA AND BREAST CANCER IN
PARAFFIN-EMBEDDED TUMOR DRAINING
LYMPH NODES BY MULTIMARKER RT-PCR

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

**TRANSMITTAL OF INFORMATION DISCLOSURE
STATEMENT**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

The information disclosure statement submitted herewith is being filed concurrently with the subject application [37 C.F.R. § 1.97(b)] and contains no items of information cited in any communication from a foreign patent office in a counterpart foreign application [37 C.F.R. § 1.97(e)(1)].

If it should be determined that for any reason either an insufficient or excessive fee has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this paper is enclosed.

Respectfully submitted,

HOGAN & HARTSON L.L.P.

By: 

Ying Chen

Registration No. 50,193

Date: November 14, 2003

Biltmore Tower
500 South Grand Avenue, Suite 1900
Los Angeles, CA 90071
Telephone: (213) 337-6700
Facsimile: (213) 337-6701

Enclosures: Form PTO-1449
Cited References

FORM PTO-1449

Docket Number
(Optional)
89212.0014Application Number
Not Yet Assigned**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION***(Use several sheets if necessary)*Applicant
Dave S.B. HOON and Hiroya TAKEUCHIFiling Date
HerewithGroup Art Unit
Not Yet Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,248,535 B1	06/19/2001	Danenberg et al.	435	6	12/20/1999
	6,331,393 B1	12/18/2001	Laird et al.	435	6	05/14/1999
	6,428,963 B2	08/06/2002	Danenberg et al.	435	6	03/01/2001
	6,518,416 B1	02/11/2003	Danenberg	536	24.33	03/02/2001
	6,573,052 B2	06/03/2003	Danenberg	435	6	06/11/2001
	6,602,670 B2	08/05/2003	Danenberg	435	6	11/20/2001
	6,610,488 B2	08/26/2003	Danenberg et al.	435	6	03/01/2001
	6,613,518 B2	09/02/2003	Danenberg et al.	435	6	03/01/2001

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Morton, D. L., Wen, D. R., Wong, J. H., Economou, J. S., Cagle, L. A., Storm, F. K., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
	Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000;231:795-803
	Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo CK, Foshag LJ, Nizze JA., Morton DL. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol., 13: 2109-16, 1995
	Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993;11:1751-6
	Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449

Docket Number
(Optional)
89212.0014Application Number
Not Yet Assigned**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION***(Use several sheets if necessary)*Applicant
Dave S.B. HOON and Hiroya TAKEUCHIFiling Date
HerewithGroup Art Unit
Not Yet Assigned**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. *Recent Results Cancer Res* 2001;158:78-92

Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A.J., Schmid, P. Morton, D. L., and Hoon D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. *Cancer Res.*, 57: 1371-1376, 1997

Bostick, P. J., Morton, D. L., Turner, R. R., Huynh K. T., Wang, H-J., Elashoff R., Essner R., and Hoon, D. S. B Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. *J. Clin. Oncol*, 17: 3238-3244, 1999

Hoon D. S. B, Bostick P., Kuo, C., Okamoto T, Wang H-J., Elashoff, R., and Morton, D. L. Molecular markers in blood a surrogate prognostic indicators of melanoma recurrence. *Cancer Res.*, 60: 2253-2257, 2000

Miyashiro, I., Kuo, C., Huynh, K., Iida A., Morton D., Bilchik, A., Giuliano A., and Hoon D. S. B. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. *Clin. Chem.* 47: 505-512, 2001

Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fix samples and optimization of molecular biology applications for such samples. *Nuc Acid Res* 1999;27:4436-43

Shirota Y, Stoeblmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. *J Clin Oncol* 2001;19:4298-304

Hoon DS, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with γ -interferon or α -tumor necrosis factor. *Cancer Res* 1991;51:2002-8

Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFA-I-1). *Proc Natl Acad Sci US* 1983;80:5392-6

Kuo CT, Bostick PJ, Irie RF, Morton DL, Conrad AJ, Hoon DS. Assessment of messenger RNA of β 1 \rightarrow 4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. *Clin Cancer Res* 1998;4:411-8

Morton DL, Barth A. Vaccine therapy for malignant melanoma. *CA Cancer J Clin* 1996;46:225-44

O'Day SJ, Boasberg PD, Piro L, Kristedja TS, et al. Maintenance biotherapy for metastatic melanoma with interleukin 2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. *Clin Cance Res* 2002;8:2775-81

Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. *Ann Clin Biochem* 1993;30:521-29

Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. *Int J Cancer* 2001;93:162-71

Bilchik, A. J., Saha, S., Wiese, D., Stonecypher, J. A., Wood, T. F., Sostrin, S., Turner, R. R., Wang, H-J., Morton D. L., and Hoon, D. S. B Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase I trial. *J. Clin. Oncol*, 19: 1128-1136, 2001

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.